单硝酸异山梨酯治疗心力衰竭的效果及对心功能影响分析.doc

单硝酸异山梨酯治疗心力衰竭的效果及对心功能影响分析
【摘要】 目的:探討单硝酸异山梨酯应用于心力衰竭治疗的临床效果及对患者心功能的影响。方法:选取2017年6月-2018年6月笔者所在医院收治的心力衰竭患者60例为研究对象,随p was significantly higher(P<).Before treatment,there were no significant differences in the levels of TNF-α,IL-6 and hs-CRP between the two groups(P>).After treatment,the levels of TNF-α,IL-6 and hs-CRP in the two groups were significantly lower than those before treatment,and which in the study group were significantly lower than those in the control group(P<).Before treatment,there were no significant differences in CI,LVEDD and LVEF between the two groups(P>).After treatment,the CI and LVEF of the two groups were significantly higher than those before treatment,and the LVEDD of the two group were lower than those before treatment,and the indexes were superior than those of the control group(P<).There were no serious adverse reactions in the two groups during :Isosorbide Mononitrate can effectively improve the curative effect,improve cardiac function and alleviate inflammation in the treatment of heart failure on the basis of routine is safe and worthy of clinical promotion. 【Key words】 Heart failure; Isosorbide mononitrate; Cytokines; Cardiac function; Clinical efficacy
First-author’s address:The First Affiliated Hospital of Xiamen University,Xiamen 361003,China
心力衰竭简称心衰,是临床常见的心脑血管疾病,主要是指由于心脏的舒张功能、收缩功能发生障碍,而不能充分将静脉的回心血量排出心脏,致使静脉系统发生血液淤积,动脉系统出现血液灌注不充分,进而引发心脏循环障碍,临床主要表现为液体潴留、体力活动受限、呼吸困难等[1-2]。心力衰竭发病率高、预后差,其5年生存期与恶性肿瘤相近,因此及时有效的治疗对改善患者预后至关重要。目前,临床上多采用β受体阻滞剂、血管紧张素Ⅱ受体拮抗剂、血管紧张素转换酶抑制剂治疗心力衰竭,并取得了一定效果,但仍有患者效果欠佳[3]。本研究主要是对单硝酸异山梨酯应用于心力衰竭治疗的临床效果及其对患者心功能的影响进行探讨,现报道如下。
1 资料与方法
一般资料
选取2017年6月-2018年6月笔者所在医院收治的心力衰竭患者60例为研究对象。纳入标准:(1)均符合心力衰竭诊断标准[4];(2)无意识障碍、精神性疾病。排除标准:(1)伴心源性休克者;(2)伴急性心肌梗死者;(3)伴恶性肿瘤者;(4)伴自身免疫性疾病者。患者均自愿参与本次研究签署知情同意书,研究符合医学伦理学要求。采用随机数字表法将60例患者随机分为研究组与对照组,各30例。研究组患者中,男18例,女12例;年龄45~73岁,平均(±)岁;病程3~9年,平均(±)年;心功能Ⅳ级17例,心功能Ⅲ级13例。对照组患者中,男16例,女14例;年龄46~75岁,平均(